85 related articles for article (PubMed ID: 20081767)
1. Are drug-eluting stents the future of SFA treatment?
Bosiers M; Deloose K; Keirse K; Verbist J; Peeters P
J Cardiovasc Surg (Torino); 2010 Feb; 51(1):115-9. PubMed ID: 20081767
[TBL] [Abstract][Full Text] [Related]
2. The potential role of DES in peripheral in-stent restenosis.
Zeller T; Macharzina R; Tepe G
J Cardiovasc Surg (Torino); 2010 Aug; 51(4):561-5. PubMed ID: 20671640
[TBL] [Abstract][Full Text] [Related]
3. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
Antoniou GA; Georgakarakos EI; Antoniou SA; Georgiadis GS
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):282-5. PubMed ID: 24729201
[TBL] [Abstract][Full Text] [Related]
4. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup.
Bosiers M; Peeters P; Tessarek J; Deloose K; Strickler S;
J Cardiovasc Surg (Torino); 2013 Feb; 54(1):115-22. PubMed ID: 23296421
[TBL] [Abstract][Full Text] [Related]
5. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty.
Marmagkiolis K; Hakeem A; Choksi N; Al-Hawwas M; Edupuganti MM; Leesar MA; Cilingiroglu M
Catheter Cardiovasc Interv; 2014 Oct; 84(4):555-64. PubMed ID: 24740749
[TBL] [Abstract][Full Text] [Related]
6. Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent.
Nguyen BN; Conrad MF; Guest JM; Hackney L; Patel VI; Kwolek CJ; Cambria RP
J Vasc Surg; 2011 Oct; 54(4):1051-1057.e1. PubMed ID: 21636240
[TBL] [Abstract][Full Text] [Related]
7. Acute and long-term outcome of Silverhawk assisted atherectomy for femoro-popliteal lesions according the TASC II classification: a single-center experience.
Sixt S; Rastan A; Beschorner U; Noory E; Schwarzwälder U; Bürgelin K; Schwarz T; Müller C; Hauk M; Brantner R; Möhrle C; Linnemann B; Macharzina R; Neumann FJ; Zeller T
Vasa; 2010 Aug; 39(3):229-36. PubMed ID: 20737381
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions.
Antonopoulos CN; Mylonas SN; Moulakakis KG; Sergentanis TN; Sfyroeras GS; Lazaris AM; Kakisis JD; Vasdekis SN
J Vasc Surg; 2017 Jan; 65(1):234-245.e11. PubMed ID: 27865639
[TBL] [Abstract][Full Text] [Related]
9. Mid-term outcome after endovascular therapy in the superficial femoral and popliteal artery using long stents.
Schoenefeld E; Donas KP; Schönefeld T; Osada N; Austermann M; Torsello G
Vasa; 2012 Jan; 41(1):49-56. PubMed ID: 22247060
[TBL] [Abstract][Full Text] [Related]
10. Are bio-absorbable stents the future of SFA treatment?
Peeters P; Keirse K; Verbist J; Deloose K; Bosiers M
J Cardiovasc Surg (Torino); 2010 Feb; 51(1):121-4. PubMed ID: 20081768
[TBL] [Abstract][Full Text] [Related]
11. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
[TBL] [Abstract][Full Text] [Related]
12. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
[TBL] [Abstract][Full Text] [Related]
13. Drug-eluting stents for treatment of focal infrapopliteal lesions.
Rastan A; Noory E; Zeller T
Vasa; 2012 Mar; 41(2):90-5. PubMed ID: 22403126
[TBL] [Abstract][Full Text] [Related]
14. Iliac artery stenting combined with open femoral endarterectomy is as effective as open surgical reconstruction for severe iliac and common femoral occlusive disease.
Piazza M; Ricotta JJ; Bower TC; Kalra M; Duncan AA; Cha S; Gloviczki P
J Vasc Surg; 2011 Aug; 54(2):402-11. PubMed ID: 21531527
[TBL] [Abstract][Full Text] [Related]
15. Which is currently the best strategy for treatment of SFA in-stent restenosis?
Elens M; Verbist J; Keirse K; Van Den Eynde W; Peeters P
J Cardiovasc Surg (Torino); 2014 Aug; 55(4):477-81. PubMed ID: 24941234
[TBL] [Abstract][Full Text] [Related]
16. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery.
Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
JACC Cardiovasc Interv; 2014 Jul; 7(7):792-8. PubMed ID: 25060024
[TBL] [Abstract][Full Text] [Related]
17. Commentary: infrapopliteal angioplasty with drug-eluting stents: from heart to toe.
Siablis D; Katsanos K; Karnabatidis D
J Endovasc Ther; 2010 Aug; 17(4):488-91. PubMed ID: 20681764
[No Abstract] [Full Text] [Related]
18. Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent.
Moukarbel GV; Burket MW
Expert Rev Med Devices; 2015 Mar; 12(2):157-62. PubMed ID: 25418344
[TBL] [Abstract][Full Text] [Related]
19. Regarding "Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions".
Dindyal S; Sharma P; Kyriakides C
J Vasc Surg; 2008 Nov; 48(5):1357; author reply 1357. PubMed ID: 18971047
[No Abstract] [Full Text] [Related]
20. Endovascular first strategy for de novo TransAtlantic Inter-Society Consensus C and D femoro-popliteal disease: mid-term outcomes from a single tertiary referral center.
Grenville JL; Tan KT; Moshonov H; Rajan DK
Vascular; 2015 Feb; 23(1):31-40. PubMed ID: 24695358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
